-
Prime Medicine Announces Proposed Public Offering of Common Stock
-
BMO Capital Highlights Favorite Names for 2025 in Biotech
-
BMO Capital Reiterates Outperform Rating on Prime Medicine (PRME)
-
BMO Capital Reiterates Outperform Rating on Prime Medicine (PRME)
-
BMO Capital Reiterates Outperform Rating on Prime Medicine (PRME)
-
Prime Medicine Announces Closing of Upsized Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares
-
Prime Medicine (PRME) Prices Upsized 19.2M Share Offering at $6.25/sh
-
Prime Medicine Announces Pricing of Upsized Public Offering
-
Prime Medicine (PRME) Announces Proposed $125M Share Offering
-
Prime Medicine Announces Proposed Public Offering of Common Stock
-
BMO Capital Starts Prime Medicine (PRME) at Outperform

